Johnson & Johnson said it will invest $2 billion over the next decade to expand drug-manufacturing capacity at Fujifilm Diosynth Biotechnologies’ campus in Holly Springs, North Carolina. The project is expected to create about 120 jobs and will equip the 160,000-square-foot facility to make advanced biologic medicines, allowing a larger share of the company’s therapies to be produced domestically. The announcement comes as the Trump administration weighs import tariffs on pharmaceuticals, a policy that could raise costs for drugs made overseas. Chief Executive Officer Joaquin Duato called the expansion part of a broader effort to deepen the company’s U.S. manufacturing base. Johnson & Johnson has disclosed $55 billion in domestic capital commitments so far this year and said additional plant expansions are forthcoming.